Search

Your search keyword '"Splinter, T. A."' showing total 161 results
Start Over Author "Splinter, T. A."
161 results on '"Splinter, T. A."'

6. Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group

Author

Aapro, M. S., van Wijk, F. H., Bolis, G., Chevallier, B., van der Burg, M. E. L., Poveda, A., de Oliveira, C. F., Tumolo, S., Scotto di Palumbo, V., Piccart, M., Franchi, M., Zanaboni, F., Lacave, A. J., Fontanelli, R., Favalli, G., Zola, P., Guastalla, J. P., Rosso, R., Marth, C., Nooij, M., Presti, M., Scarabelli, C., Splinter, T. A. W., Ploch, E., Beex, L. V. A., ten Bokkel Huinink, W., Forni, M., Melpignano, M., Blake, P., Kerbrat, P., Mendiola, C., Cervantes, A., Goupil, A., Harper, P. G., Madronal, C., Namer, M., Scarfone, G., Stoot, J. E. G. M., Teodorovic, I., Coens, C., Vergote, I., and Vermorken, J. B.

Published
2003

19. Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group

Author

Aapro, M. S., van Wijk, F. H., Bolis, G., Chevallier, B., van der Burg, M. E. L., Poveda, A., de Oliveira, C. F., Tumolo, S., Scotto di Palumbo, V., Piccart, M., Franchi, M., Zanaboni, F., Lacave, A. J., Fontanelli, R., Favalli, G., Zola, P., Guastalla, J. P., Rosso, R., Marth, C., Nooij, M., Presti, M., Scarabelli, C., Splinter, T. A. W., Ploch, E., Beex, L. V. A., ten Bokkel Huinink, W., Forni, M., Melpignano, M., Blake, P., Kerbrat, P., Mendiola, C., Cervantes, A., Goupil, A., Harper, P. G., Madronal, C., Namer, M., Scarfone, G., Stoot, J. E. G. M., Teodorovic, I., Coens, C., Vergote, I., Vermorken, J. B., Aapro, M. S., van Wijk, F. H., Bolis, G., Chevallier, B., van der Burg, M. E. L., Poveda, A., de Oliveira, C. F., Tumolo, S., Scotto di Palumbo, V., Piccart, M., Franchi, M., Zanaboni, F., Lacave, A. J., Fontanelli, R., Favalli, G., Zola, P., Guastalla, J. P., Rosso, R., Marth, C., Nooij, M., Presti, M., Scarabelli, C., Splinter, T. A. W., Ploch, E., Beex, L. V. A., ten Bokkel Huinink, W., Forni, M., Melpignano, M., Blake, P., Kerbrat, P., Mendiola, C., Cervantes, A., Goupil, A., Harper, P. G., Madronal, C., Namer, M., Scarfone, G., Stoot, J. E. G. M., Teodorovic, I., Coens, C., Vergote, I., and Vermorken, J. B.

Abstract

Background: Combination chemotherapy yields better response rates which do not always lead to a survival advantage. The aim of this study was to investigate whether the reported differences in the efficacy and toxicity of monotherapy with doxorubicin (DOX) versus combination therapy with cisplatin (CDDP) in endometrial adenocarcinoma lead to significant advantage in favour of the combination. Patients and methods: Eligible patients had histologically-proven advanced and/or recurrent endometrial adenocarcinoma and were chemo-naïve. Treatment consisted of either DOX 60 mg/m2 alone or CDDP 50 mg/m2 added to DOX 60 mg/m2, every 4 weeks. Results: A total of 177 patients were entered and median follow-up is 7.1 years. The combination DOX-CDDP was more toxic than DOX alone. Haematological toxicity consisted mainly of white blood cell toxicity grade 3 and 4 (55% versus 30%). Non-haematological toxicity consisted mainly of grade 3 and 4 alopecia (72% versus 65%) and nausea/vomiting (36 % versus 12%). The combination DOX-CDDP provided a significantly higher response rate than single agent DOX (P <0.001). Thirty-nine patients (43%) responded on DOX-CDDP [13 complete responses (CRs) and 26 partial responses (PRs)], versus 15 patients (17%) on DOX alone (8 CR and 7 PR). The median overall survival (OS) was 9 months in the DOX-CDDP arm versus 7 months in the DOX alone arm (Wilcoxon P = 0.0654). Regression analysis showed that WHO performance status was statistically significant as a prognostic factor for survival, and stratifying for this factor, treatment effect reaches significance (hazard ratio = 1.46, 95% confidence interval 1.05-2.03, P = 0.024). Conclusions: In comparison to single agent DOX, the combination of DOX-CDDP results in higher but acceptable toxicity. The response rate produced is significantly higher, and a modest survival benefit is achieved with this combination regimen, especially in patients with a good performance status

Published
2017

23. Cisplatin and etoposide in oesophageal cancer: a phase II study. Rotterdam Oesophageal Tumour Study Group

Author

Kok, T. C., Van der Gaast, A., Dees, J., Eykenboom, W. M., Van Overhagen, H., Stoter, G., Tilanus, H. W., and Splinter, T. A.

Subjects
Adult, Male, Survival Rate, Esophageal Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Humans, Female, Cisplatin, Middle Aged, Research Article, Aged, Etoposide
Abstract

In the search for effective chemotherapy regimens which can be used in multimodality treatment programmes for patients with cancer of the oesophagus, we conducted a phase II trial to determine the activity and toxicity of the combination of cisplatin and etoposide in patients with advanced squamous cell carcinoma of the oesophagus. Seventy-three consecutive patients with unresectable or metastatic squamous cell carcinoma of the thoracic oesophagus were treated with cisplatin 80 mg m-2 by 4 h infusion on day 1, etoposide 100 mg (fixed dose) by 2 h infusion on day 1 and 2, and etoposide 200 mg m-2 orally on day 3 and 5. Courses were repeated every 4 weeks, for a maximum of six courses. The oral dosages of etoposide were modified individually until a significant degree of myelosuppression was reached. Of 65 evaluable patients, five complete responses (CRs) and 26 partial responses (PRs) were seen, for an overall response rate of 48% (95% confidence interval 35-60%). Median time to progression was 7 months (range 3-72 + months). There were two toxic deaths (neutropenic sepsis). The response rate equals that of other cisplatin-based regimens. Its toxicity profile allows addition of a third active drug such as 5-fluorouracil.

Published
1996

24. Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874)

Author

Reed, Ns, Mangioni, C, Malmström, H, Scarfone, G, Poveda, A, Pecorelli, S, Tateo, S, Franchi, M, Jobsen, Jj, Coens, C, Teodorovic, I, Vergote, I, Vermorken, Jb, Malmstrom, H, Favalli, G, Jobsen, J, van Bunningen, B, Splinter, T, van der Burg ME, Drouin, P, Zola, Paolo, Frankendaal, B, Schepansky, A, Swenerton, K, Stuart, G, Scarabelli, C, Mangili, G, van Rijswijk, R, Van, Putten, Chevalier, B, Stoot, Je, Beex, L, Souhami, L, Heintz, Ap, Bonnefoi, H, Koelbl, H, Kobierska, A, Guthrie, D, Maggino, T, di Palumbo VS, Bessette, P, van Wijk, A, and Verheijen, R.

Subjects
Adult, Leiomyosarcoma, Oncology, Cancer Research, medicine.medical_specialty, Randomization, Sarcoma, Endometrial Stromal, medicine.medical_treatment, Disease-Free Survival, Carcinosarcoma, Internal medicine, medicine, Humans, Stage (cooking), Aged, Aged, 80 and over, uterine sarcoma radiotherapy, Radiotherapy, Uterine sarcoma, business.industry, Cancer, Middle Aged, Pelvic cavity, medicine.disease, Surgery, Radiation therapy, Clinical trial, Treatment Outcome, medicine.anatomical_structure, Uterine Neoplasms, Disease Progression, Female, Radiotherapy, Adjuvant, Neoplasm Recurrence, Local, business, Adjuvant
Abstract

The management of uterine sarcomas continues to present many difficulties. Primary surgery is the optimal treatment but the role of post-operative radiation remains uncertain. In the mid-1980s, the European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study proposed a trial to evaluate adjuvant radiotherapy, as previous non-randomised studies had suggested a survival advantage and improved local control when post-operative radiation was administered. The study opened in 1987 taking 13 years to accrue 224 patients. All uterine sarcoma subtypes were permitted. Patients were required to have undergone as a minimum, TAH and BSO and wahsings (166 patients) but nodal sampling was optional. There were 103 leiomyosarcomas (LMS), 91 carcinosarcomas (CS) and 28 endometrial stromal sarcomas (ESS). Patients were randomised to either observation or pelvic radiation, 51Gy in 28 fractions over 5 weeks. Hundred and twelve were recruited to each arm. The initial analysis has shown a reduction in local relapse (14 versus 24, p =0.004) but no effect on either OS or PFS. No unexpected toxicity was seen in the radiation arm. No difference in either overall or disease-free survival was demonstrated but there is an increased local control for the CS patients receiving radiation but without any benefit for LMS. Prognostic factor analysis shows that stage, age and histological subtype were important predictors of behaviour which may explain differences between CS and LMS. CS appears to show more kinship to poorly differentiated endometrial carcinomas in behaviour. LMS did not show the same benefit from radiation. These results will help shape future management and clinical trials in uterine sarcomas.

Published
2008

28. Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer

Author

Giaccone, G., Splinter, T. A., Debruyne, C., Kho, G. S., Lianes, P., Nico van Zandwijk, Pennucci, M. C., Scagliotti, G., Meerbeeck, J., Hoesel, Q., Curran, D., Sahmoud, T., Postmus, P. E., Medical Oncology, and Pulmonary Medicine

Subjects
Adult, Male, Aged, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Cisplatin, Female, Humans, Lung Neoplasms, Middle Aged, Paclitaxel, Quality of Life, Random Allocation, Survival Rate, Teniposide, Treatment Outcome, Oncology, Cancer Research, Carcinoma, Experimental diagnostics and therapy of malignancies, SDG 3 - Good Health and Well-being, Non-Small-Cell Lung
Abstract

Item does not contain fulltext

Published
1998

29. Quality assurance of thoracic radiotherapy in EORTC 08941: a randomised trial of surgery versus thoracic radiotherapy in patients with stage IIIA non-small-cell lung cancer (NSCLC) after response to induction chemotherapy.

Author

Kramer, G.W.P.M., Legrand, C., Schil, P. van, Uitterhoeve, L., Smit, E.F., Schramel, F.M., Biesma, B., Tjan-Heijnen, V.C., Zandwijk, N. van, Splinter, T., Giaccone, G., Meerbeeck, J.P. van, Kramer, G.W.P.M., Legrand, C., Schil, P. van, Uitterhoeve, L., Smit, E.F., Schramel, F.M., Biesma, B., Tjan-Heijnen, V.C., Zandwijk, N. van, Splinter, T., Giaccone, G., and Meerbeeck, J.P. van

Abstract

Contains fulltext : 50144.pdf (publisher's version ) (Closed access), The aim of this study was to investigate the improvement of quality of radiotherapy and compliance to the protocol amendment of EORTC study 08941. The radiotherapy-specific data were analysed from 154 patients with stage IIIA-N2 Non-Small-Cell Lung Cancer who were actually irradiated after response to 3 cycles of platinum-based induction chemotherapy. The parameters of quality, assessed in 93 patients before and in 61 after protocol amendment, included: time interval between last chemotherapy course and start of thoracic radiotherapy, the use of a 3-D planning CT, dose and fractionation scheme to the primary tumour, the involved and uninvolved mediastinum, duration of radiotherapy and toxicity. A significant improvement of all quality parameters was noted, except for the overall treatment time, which decreased slightly. Protocol amendment resulted in an improvement of the quality and the compliance of most observed parameters, at the cost of some increase in overall treatment time. The latter reflects logistical problems rather than poor compliance.

Published
2006

33. Randomized Controlled Trial of Resection Versus Radiotherapy After Induction Chemotherapy in Stage IIIA-N2 Non-Small-Cell Lung Cancer

Author

van Meerbeeck, J. P., primary, Kramer, G. W. P. M., additional, Van Schil, P. E. Y., additional, Legrand, C., additional, Smit, E. F., additional, Schramel, F., additional, Tjan-Heijnen, V. C., additional, Biesma, B., additional, Debruyne, C., additional, van Zandwijk, N., additional, Splinter, T. A. W., additional, and Giaccone, G., additional

Published
2007
Full Text
View/download PDF

34. Pr5 A randomized trial of radical surgery (S) versus thoracicradiotherapy (TRT) in patients (pts) with stage IIIA-N2 non-small cell lung cancer (NSCLC) after response to induction chemotherapy (ICT) (EORTC 08941)

Author

van Meerkbeeck, J., primary, Van Schil, P., additional, Kramer, G., additional, Legrand, C., additional, O'Brien, M., additional, Manegold, C., additional, Passioukov, A., additional, Giaccone, G., additional, van Zandwijk, N., additional, and Splinter, T., additional

Published
2005
Full Text
View/download PDF

35. PD-045 Quality assurance review of thoracic radiotherapy inEORTC 08941: A randomized trial of surgery (S) versus thoracic radiotherapy (RT) in patients (pts) with stage IIIA non-small-cell lung cancer (NSCLC) after response to induction chemotherapy (ICT)

Author

Kramer, G., primary, van Meerbeeck, J., additional, van Schil, P., additional, Uitterhoeve, L., additional, Smit, E., additional, Schramel, F., additional, Biesma, B., additional, Tjan-Heijnen, V., additional, Legrand, C., additional, and Splinter, T., additional

Published
2005
Full Text
View/download PDF

40. D-TRP-6-LHRH (Triptorelin) is not effective in ovarian carcinoma: an EORTC Gynaecological Cancer Co-operative Group Study

Author

Duffaud, F, primary, van der Burg, M EL, additional, Namer, M, additional, Vergote, I, additional, Willemse, P B, additional, ten Bokkel Huinink, W, additional, Guastalla, J P, additional, Nooij, M A, additional, Kerbrat, P, additional, Piccart, M, additional, Tumolo, S, additional, Favalli, G, additional, van der Vange, N, additional, Lacave, A J, additional, Wils, J, additional, Splinter, T AW, additional, Einhorn, N, additional, Roozendaal, K J, additional, Rosso, R, additional, and Vermorken, J B, additional

Published
2001
Full Text
View/download PDF

42. European School of Oncology. First Euro-American Forum on Lung Cancer Treatment.

Author

UCL - (SLuc) Unité d'oncologie médicale, Bunn, P A, Van Zandwijk, N, Pastorino, U, Aisner, J, Alberto, P, Arriagada, R, Carney, D, Cornis, R, Dittrich, C, Gatzemeier, U, Ginsberg, R., Greco, FA, Hansen, HH, Harper, P., Henriksson, R., Huber, H., Klener, P., Lechevalier, T., Lewensohn, R., Murray, N., Niederle, N., Postmus, P., Rosell, R., Scagliotti, G., Sculier, JP, Splinter, T., Stahel, R., Symann, Michel, Thatcher, N., Tonato, M., Turrisi, A., UCL - (SLuc) Unité d'oncologie médicale, Bunn, P A, Van Zandwijk, N, Pastorino, U, Aisner, J, Alberto, P, Arriagada, R, Carney, D, Cornis, R, Dittrich, C, Gatzemeier, U, Ginsberg, R., Greco, FA, Hansen, HH, Harper, P., Henriksson, R., Huber, H., Klener, P., Lechevalier, T., Lewensohn, R., Murray, N., Niederle, N., Postmus, P., Rosell, R., Scagliotti, G., Sculier, JP, Splinter, T., Stahel, R., Symann, Michel, Thatcher, N., Tonato, M., and Turrisi, A.

Published
1994

45. A double-blind, multicentre comparison of intravenous dolasetron mesilate and metoclopramide in the prevention of nausea and vomiting in cancer patients receiving high-dose cisplatin chemotherapy

Author

Chevallier, B., primary, Cappelaere, P., additional, Splinter, T., additional, Fabbro, M., additional, Wendling, J. L., additional, Cals, L., additional, Catimel, G., additional, Giovannini, M., additional, Khayat, D., additional, Bastit, P., additional, and Claverie, N., additional

Published
1996
Full Text
View/download PDF

46. Two schedules of teniposide with or without cisplatin in advanced non-small-cell lung cancer: a randomized study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group.

Author

Splinter, T A, primary, Sahmoud, T, additional, Festen, J, additional, van Zandwijk, N, additional, Sörenson, S, additional, Clerico, M, additional, Burghouts, J, additional, Dautzenberg, B, additional, Kho, G S, additional, Kirkpatrick, A, additional, and Giaccone, G, additional

Published
1996
Full Text
View/download PDF

49. Prognostic factors in non-small cell lung cancer

Author

Feld, R., primary, Borges, M., additional, Giner, V., additional, Ginsberg, R., additional, Harper, P., additional, Klastersky, J., additional, Lacquet, L., additional, Paesmans, M., additional, Payne, D., additional, Rossell, R., additional, Sause, W., additional, Sculier, J.P., additional, Shaw, E., additional, Sorensen, J.B., additional, Splinter, T., additional, Stahel, R., additional, and Bunn, P., additional

Published
1994
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results